Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation?

Abstract

Thrombin triggers activation of platelets through protease-activated receptor 1 (PAR-1) and PAR-4. Both receptors are widely expressed and exert multiple platelet-independent functions. PAR signalling contributes to healing responses after injury, by promoting cytokine activity and cellular growth and mobility. Uncontrolled PAR activation, however, can prevent timely resolution of inflammation, enhance thrombogenic endothelial function and drive adverse remodelling. The specific role of PAR-4 in thromboinflammatory vascular disease has been largely underestimated, given the relatively limited expression of PAR-4 in non-platelet cells under healthy conditions. However, unlike PAR-1, PAR-4 expression adapts dynamically to numerous stimuli associated with thromboinflammation, including thrombin, angiotensin II, sphingosine-1-phosphate (S1P), high glucose and redox stress, suggesting expression is switched on ‘at need’. Prostacyclin negatively regulates PAR-4 expression at the post-transcriptional level, which may serve to fine-tune thrombin responses and limit these to the injury site. PAR-4 elicits inflammatory, mitogenic and proliferative actions not only in response to thrombin but also to numerous other inflammatory proteases, and can cross-talk with other receptor systems such as S1P and adenosine receptors. Accordingly, PAR-4 has emerged as a candidate player in vessel disease and cardiac post-infarction remodelling. Currently, PAR-4 is a particularly promising target for safer anti-thrombotic therapies. Recent studies with the PAR-4 antagonist BMS-986120 lend support to the concept that selective antagonism of PAR-4 may offer both an effective and safe anti-thrombotic therapy in the acute thrombotic setting as well as an anti-inflammatory strategy to prevent long-term progressive atherosclerotic disease in high-risk cardiovascular patients.

Keywords

thrombin - thromboinflammation - protease-activated receptor - vascular - antagonist

• References

• 1 Witkowski M, Landmesser U, Rauch U. Tissue factor as a link between inflammation and coagulation. Trends Cardiovasc Med 2016; 26 (04) 297-303
• 2 Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103 (06) 879-887
• 3 Kahn ML, Zheng YW, Huang W. , et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394 (6694): 690-694
• 4 Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413 (6851): 74-78
• 5 Mihara K, Ramachandran R, Saifeddine M. , et al. Thrombin-mediated direct activation of proteinase-activated receptor-2: another target for thrombin signaling. Mol Pharmacol 2016; 89 (05) 606-614
• 6 Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000; 404 (6778): 609-613
• 7 Steinberg SF. The cardiovascular actions of protease-activated receptors. Mol Pharmacol 2005; 67 (01) 2-11
• 8 Sidhu TS, French SL, Hamilton JR. Differential signaling by protease-activated receptors: implications for therapeutic targeting. Int J Mol Sci 2014; 15 (04) 6169-6183
• 9 Khan A, Li D, Ibrahim S, Smyth E, Woulfe DS. The physical association of the P2Y12 receptor with PAR4 regulates arrestin-mediated Akt activation. Mol Pharmacol 2014; 86: 1-11
• 10 Leger AJ, Jacques SL, Badar J. , et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 2006; 113: 1244-54
• 11 Lin H, Liu AP, Smith TH, Trejo J. Cofactoring and dimerization of proteinase-activated receptors. Pharmacol Rev 2013; 65: 1198-213
• 12 McLaughlin JN, Patterson MM, Malik AB. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci USA 2007; 104: 5662-7
• 13 Erhardt JA, Toomey JR, Douglas SA, Johns DG. P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation. J Thromb Haemost 2006; 4: 882-90
• 14 Bernlochner I, Sibbing D. Thienopyridines and other ADP-receptor antagonists. Handbook Exp Pharmacol 2012; 165-98
• 15 Holinstat M, Voss B, Bilodeau ML. , et al. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation. J Biol Chem 2006; 281: 26665-74
• 16 Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem 2000; 275: 25216-21
• 17 Badr Eslam R, Lang IM, Koppensteiner R. , et al. Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. Int J Cardiol 2013; 168: 403-6
• 18 Schrör K, Bretschneider E, Fischer K. , et al. Thrombin receptors in vascular smooth muscle cells - function and regulation by vasodilatory prostaglandins. Thromb Haemost 2010; 103: 884-90
• 19 Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-52
• 20 Rosenkranz AC, Schror K, Rauch BH. Direct inhibitors of thrombin and factor Xa attenuate clot-induced mitogenesis and inflammatory gene expression in human vascular smooth muscle cells. Thromb Haemost 2011; 106: 561-2
• 21 Kolpakov MA, Rafiq K, Guo X. , et al. Protease-activated receptor 4 deficiency offers cardioprotection after acute ischemia reperfusion injury. J Mol Cell Cardiol 2016; 90: 21-9
• 22 French SL, Hamilton JR. Protease-activated receptor 4: from structure to function and back again. Br J Pharmacol 2016
• 23 Pavic G, Grandoch M, Dangwal S. , et al. Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus. Circulation 2014; 130: 1700-11
• 24 Wygrecka M, Didiasova M, Berscheid S. , et al. Protease-activated receptors (PAR)-1 and -3 drive epithelial-mesenchymal transition of alveolar epithelial cells - potential role in lung fibrosis. Thromb Haemost 2013; 110: 295-307
• 25 Tiburcio M, Costa SM, , M DEFD, Schmitt FC, Longatto Filho A. Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic significance. Oncol Lett 2012; 4: 647-57
• 26 Snead AN, Insel PA. Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts. FASEB J 2012; 26 (11) 4540-7
• 27 Han N, Jin K, He K, Cao J, Teng L. Protease-activated receptors in cancer: A systematic review. Oncol Lett 2011; 2: 599-608
• 28 Dabek M, Ferrier L, Annahazi A. , et al. Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice: role of cathepsin G and protease-activated receptor-4. Inflamm Bowel Dis 2011; 17: 1409-14
• 29 Antoniak S, Pawlinski R, Mackman N. Protease-activated receptors and myocardial infarction. IUBMB Life 2011; 63: 383-9
• 30 Mao Y, Zhang M, Tuma RF, Kunapuli SP. Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice. J Cereb Blood Flow Metab 2010; 30: 1044-52
• 31 Shah R. Protease-activated receptors in cardiovascular health and diseases. Am Heart J 2009; 157: 253-62
• 32 Shpacovitch V, Feld M, Hollenberg MD, Luger TA, Steinhoff M. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J LeukocBiol 2008; 83: 1309-22
• 33 Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006; 114: 1070-7
• 34 Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood 2015; 125: 2898-907
• 35 Mutch NJ, Robbie LA, Booth NA. Human thrombi contain an abundance of active thrombin. Thromb Haemost 2001; 86: 1028-34
• 36 Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. J Clin Invest 1989; 84: 1096-104
• 37 Bonaca MP, Scirica BM, Creager MA. , et al. Vorapaxar in patients with peripheral artery disease: results from TRA2P-TIMI 50. Circulation 2013; 127: 1522-9 , 9e1-6
• 38 Borissoff JI, Spronk HM, Heeneman S, ten Cate H. Is thrombin a key player in the 'coagulation-atherogenesis' maze?. Cardiovasc Res 2009; 82: 392-403
• 39 Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost 2001; 86: 298-307
• 40 Fisslthaler B, Schini-Kerth VB, Fleming I, Busse R. Thrombin receptor expression is increased by angiotensin II in cultured and native vascular smooth muscle cells. Cardiovasc Res 1998; 38: 263-71
• 41 Fukunaga R, Hirano K, Hirano M. , et al. Upregulation of proteinase-activated receptors and hypercontractile responses precede development of arterial lesions after balloon injury. Am J Physiol Heart Circ Physiol 2006; 291: H2388-95
• 42 Hirano K. The Roles of Proteinase-Activated Receptors in the Vascular Physiology and Pathophysiology. Arterioscler Thromb Vasc Biol 2006
• 43 Napoli C, de Nigris F, Wallace JL. , et al. Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions. J Clin Pathol 2004; 57: 513-6
• 44 Bretschneider E, Kaufmann R, Braun M. , et al. Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. Br J Pharmacol 2001; 132: 1441-6
• 45 Bretschneider E, Spanbroek R, Lotzer K, Habenicht AJ, Schrör K. Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells. Thromb Haemost 2003; 90: 704-9
• 46 Bretschneider E, Uzonyi B, Weber AA. , et al. Human vascular smooth muscle cells express functionally active endothelial cell protein C receptor. Circ Res 2007; 100: 255-62
• 47 Bretschneider E, Wittpoth M, Weber AA, Glusa E, Schrör K. Thrombin but not thrombin receptor activating peptide is mitogenic for coronary artery smooth muscle cells. Thromb Res 1997; 87: 493-7
• 48 Dangwal S, Rauch BH, Gensch T. , et al. High glucose enhances thrombin responses via protease-activated receptor-4 in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2011; 31: 624-33
• 49 Mahajan SG, Fender AC, Meyer-Kirchrath J. , et al. A novel function of FoxO transcription factors in thrombin-stimulated vascular smooth muscle cell proliferation. Thromb Haemost 2012; 108: 148-58
• 50 Pape R, Rauch BH, Rosenkranz AC, Kaber G, Schrör K. Transcriptional Inhibition of Protease-Activated Receptor-1 Expression by Prostacyclin in Human Vascular Smooth Muscle Cells. Arterioscler Thromb Vasc Biol 2007
• 51 Rabausch K, Bretschneider E, Sarbia M. , et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 2005; 96: e1-6
• 52 Rosenkranz AC, Rauch BH, Doller A. , et al. Regulation of human vascular protease-activated receptor-3 through mRNA stabilization and the transcription factor nuclear factor of activated T Cells (NFAT). Mol Pharmacol 2011; 80: 337-44
• 53 Rosenkranz AC, Rauch BH, Freidel K, Schrör K. Regulation of protease-activated receptor-1 by vasodilatory prostaglandins via NFAT. Cardiovasc Res 2009; 83: 778-84
• 54 Aman M, Hirano M, Kanaide H, Hirano K. Upregulation of Proteinase-Activated Receptor-2 and Increased Response to Trypsin in Endothelial Cells after Exposure to Oxidative Stress in Rat Aortas. J Vasc Res 2010; 47: 494-506
• 55 Damiano BP, D'Andrea MR, de Garavilla L, Cheung WM, Andrade-Gordon P. Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery. Thromb Haemost 1999; 81: 808-14
• 56 Hamilton JR, Frauman AG, Cocks TM. Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res 2001; 89: 92-8
• 57 Jesmin S, Gando S, Zaedi S, Sakuraya F. Differential expression, time course and distribution of four PARs in rats with endotoxin-induced acute lung injury. Inflammation 2007; 30: 14-27
• 58 Ritchie E, Saka M, Mackenzie C. , et al. Cytokine upregulation of proteinase-activated-receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinase beta in human endothelial cells. Br J Pharmacol 2007; 150: 1044-54
• 59 Roviezzo F, Bucci M, Brancaleone V. , et al. Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes. Arterioscler Thromb Vasc Biol 2005; 25: 2349-54
• 60 Nelken NA, Soifer SJ, O'Keefe J. , et al. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90: 1614-21
• 61 Mahajan-Thakur S, Sostmann BD, Fender AC. , et al. Sphingosine-1-phosphate induces thrombin receptor PAR-4 expression to enhance cell migration and COX-2 formation in human monocytes. J Leukoc Biol 2014; 96: 611-8
• 62 Jobi K, Rauch BH, Dangwal S. , et al. Redox regulation of human protease-activated receptor-2 by activated factor X. Free Radic Biol Med 2011; 51: 1758-64
• 63 Hamilton JR, Moffatt JD, Frauman AG, Cocks TM. Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries. J Cardiovasc Pharmacol 2001; 38: 108-19
• 64 Kahn ML, Hammes SR, Botka C, Coughlin SR. Gene and locus structure and chromosomal localization of the protease-activated receptor gene family. J Biol Chem 1998; 273: 23290-6
• 65 Pullmann Jr. R, Juhaszova M, Lopez de Silanes I. , et al. Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA-binding protein HuR. J Biol Chem 2005; 280: 22819-26
• 66 Sedlyarov V, Fallmann J, Ebner F. , et al. Tristetraprolin binding site atlas in the macrophage transcriptome reveals a switch for inflammation resolution. Mol Syst Biol 2016; 12: 868
• 67 Kim Y, Noren Hooten N, Dluzen DF. , et al. Posttranscriptional Regulation of the Inflammatory Marker C-Reactive Protein by the RNA-Binding Protein HuR and MicroRNA 637. Mol Cell Biol 2015; 35: 4212-21
• 68 Dong R, Lu JG, Wang Q. , et al. Stabilization of Snail by HuR in the process of hydrogen peroxide induced cell migration. Biochem Biophys Res Commun 2007; 356: 318-21
• 69 Doller A, Akool el S, Huwiler A. , et al. Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol Cell Biol 2008; 28: 2608-25
• 70 Morris BJ, Adams DJ, Beveridge DJ. , et al. cAMP controls human renin mRNA stability via specific RNA-binding proteins. Acta Physiol Scand 2004; 181: 369-73
• 71 Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-5
• 72 Bishop-Bailey D, Pepper JR, Larkin SW, Mitchell JA. Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids. Arterioscler Thromb Vasc Biol 1998; 18: 1655-61
• 73 Rimarachin JA, Jacobson JA, Szabo P. , et al. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb 1994; 14: 1021-31
• 74 Syeda F, Grosjean J, Houliston RA. , et al. Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem 2006; 281: 11792-804
• 75 Rullier A, Senant N, Kisiel W. , et al. Expression of protease-activated receptors and tissue factor in human liver. Virchows Arch 2006; 448: 46-51
• 76 Mende K, Reifart J, Rosentreter D. , et al. Targeting platelet migration in the postischemic liver by blocking protease-activated receptor 4. Transplantation 2014; 97: 154-60
• 77 Li X, Syrovets T, Paskas S, Laumonnier Y, Simmet T. Mature dendritic cells express functional thrombin receptors triggering chemotaxis and CCL18/pulmonary and activation-regulated chemokine induction. J Immunol 2008; 181: 1215-23
• 78 Houle S, Papez MD, Ferazzini M, Hollenberg MD, Vergnolle N. Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. Br J Pharmacol 2005; 146: 670-8
• 79 Hirano K, Nomoto N, Hirano M. , et al. Distinct Ca2+ requirement for NO production between proteinase-activated receptor 1 and 4 (PAR1 and PAR4) in vascular endothelial cells. J Pharmacol Exp Ther 2007; 322: 668-77
• 80 Kaplan ZS, Zarpellon A, Alwis I. , et al. Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4. Nat Commun 2015; 6: 7835
• 81 Fu Q, Cheng J, Gao Y. , et al. Protease-activated receptor 4: a critical participator in inflammatory response. Inflammation 2015; 38: 886-95
• 82 Jani PK, Schwaner E, Kajdacsi E. , et al. Complement MASP-1 enhances adhesion between endothelial cells and neutrophils by up-regulating E-selectin expression. Mol Immunol 2016; 75: 38-47
• 83 Megyeri M, Mako V, Beinrohr L. , et al. . Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function. J Immunol 2009; 183: 3409-16
• 84 Sambrano GR, Huang W, Faruqi T. , et al. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 2000; 275: 6819-23
• 85 Wu CC, Hwang TL, Liao CH. , et al. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb Haemost 2002; 87: 1026-33
• 86 Ramachandran R, Sadofsky LR, Xiao Y. , et al. Inflammatory mediators modulate thrombin and cathepsin-G signaling in human bronchial fibroblasts by inducing expression of proteinase-activated receptor-4. Am J Physiol 2007; 292: L788-98
• 87 Baltus T, von Hundelshausen P, Mause SF. , et al. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol 2005; 78: 435-41
• 88 Mahajan-Thakur S, Bohm A, Jedlitschky G, Schror K, Rauch BH. Sphingosine-1-Phosphate and Its Receptors: A Mutual Link between Blood Coagulation and Inflammation. Mediators Inflamm 2015; 2015: 831059
• 89 Rauch BH. Sphingosine 1-phosphate as a link between blood coagulation and inflammation. Cell Physiol Biochem 2014; 34: 185-96
• 90 Bar-Shavit R, Kahn A, Fenton JW, Wilner GD. Chemotactic response of monocytes to thrombin. J Cell Biol 1983; 96: 282-5
• 91 Soslau G, Goldenberg SJ, Class R, Jameson B. Differential activation and inhibition of human platelet thrombin receptors by structurally distinct alpha-, beta- and gamma-thrombin. Platelets 2004; 15: 155-66
• 92 Hechler B, Gachet C. Purinergic Receptors in Thrombosis and Inflammation. Arterioscler Thromb Vasc Biol 2015; 35: 2307-15
• 93 Nylander S, Schulz R. Effects of P2Y12 receptor antagonists beyond platelet inhibition–comparison of ticagrelor with thienopyridines. Br J Pharmacol 2016; 173: 1163-78
• 94 Willerson JT, Cable G, Yeh ET. PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. Texas Heart Inst J 2009; 36: 530-9
• 95 Kalantzi KI, Dimitriou AA, Milionis HJ, Goudevenos IA, Tselepis AD. Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes. J Thromb Haemost 2011; 9: 875-8
• 96 Antonino MJ, Mahla E, Bliden KP, Tantry US, Gurbel PA. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol 2009; 103: 1546-50
• 97 Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Luscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007; 12: 113-22
• 98 Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharm Ther 2002; 71: 176-85
• 99 Gachet C. P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells. Purin Signal 2012; 8: 609-19
• 100 Shanker G, Kontos JL, Eckman DM, Wesley-Farrington D, Sane DC. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis 2006; 22: 213-20
• 101 Wihlborg AK, Wang L, Braun OO. , et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004; 24: 1810-5
• 102 Rauch BH, Rosenkranz AC, Ermler S. , et al. Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions. Arterioscler Thromb Vasc Biol 2010; 30: 2434-42
• 103 Li D, D'Angelo L, Chavez M, Woulfe DS. Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets. J Biol Chem 2011; 286: 3805-14
• 104 Yun LW, Decarlo AA, Hunter N. Blockade of protease-activated receptors on T cells correlates with altered proteolysis of CD27 by gingipains of Porphyromonas gingivalis. Clin Exp Immunol 2007; 150: 217-29
• 105 Gomides LF, Lima OC, Matos NA. , et al. Blockade of proteinase-activated receptor 4 inhibits neutrophil recruitment in experimental inflammation in mice. Inflamm Res 2014; 63: 935-41
• 106 Slofstra SH, Bijlsma MF, Groot AP. , et al. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood 2007; 110: 3176-82
• 107 Li T, Wang H, He S. Induction of interleukin-6 release from monocytes by serine proteinases and its potential mechanisms. Scand J Immunol 2006; 64: 10-6
• 108 Vergnolle N, Derian CK, D'Andrea MR, Steinhoff M, Andrade-Gordon P. Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. J Immunol 2002; 169: 1467-73
• 109 Herter JM, Rossaint J, Zarbock A. Platelets in inflammation and immunity. J Thromb Haemost 2014; 12: 1764-75
• 110 Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol 2013; 35: 254-61
• 111 Koenen RR. The prowess of platelets in immunity and inflammation. Thromb Haemost 2016; 116: 605-12
• 112 Mantovani A, Garlanda C. Platelet-macrophage partnership in innate immunity and inflammation. Nat Immunol 2013; 14: 768-70
• 113 Kraemer BF, Campbell RA, Schwertz H. , et al. Novel anti-bacterial activities of beta-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathog 2011; 7: e1002355
• 114 Perkhofer S, Kainzner B, Kehrel BE. , et al. Potential antifungal effects of human platelets against zygomycetes in vitro. J Infect Dis 2009; 200: 1176-9
• 115 Perkhofer S, Kehrel BE, Dierich MP. , et al. Human platelets attenuate Aspergillus species via granule-dependent mechanisms. J Infect Dis 2008; 198: 1243-6
• 116 Thomas MR, Storey RF. Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost 2015; 114: 490-7
• 117 Storey RF, James SK, Siegbahn A. , et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2014; 25: 517-25
• 118 Blasco-Colmenares E, Perl TM, Guallar E. , et al. Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med 2009; 169: 788-96
• 119 van Holten TC, Bleijerveld OB, Wijten P. , et al. Quantitative proteomics analysis reveals similar release profiles following specific PAR-1 or PAR-4 stimulation of platelets. Cardiovasc Res 2014; 103: 140-6
• 120 Falker K, Haglund L, Gunnarsson P. , et al. Protease-activated receptor 1 (PAR1) signalling desensitization is counteracted via PAR4 signalling in human platelets. Biochem J 2011; 436: 469-80
• 121 Duvernay M, Young S, Gailani D, Schoenecker J, Hamm HE. Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets. Mol Pharmacol 2013; 83: 781-92
• 122 Chatterjee M, Huang Z, Zhang W. , et al. Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood 2011; 117: 3907-11
• 123 Chatterjee M, Behrendt A, Schmid M. , et al. Platelets as a novel source of Gremlin-1: Implications for thromboinflammation. Thromb Haemost 2017; 117: 311-24
• 124 de Stoppelaar SF, Van't Veer C, van den Boogaard FE. , et al. Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice. Thromb Haemost 2013; 110: 582-92
• 125 Gleissner CA, Shaked I, Erbel C. , et al. CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circ Res 2010; 106: 203-11
• 126 Gleissner CA. Macrophage Phenotype Modulation by CXCL4 in Atherosclerosis. Front Physiol 2012; 3: 1
• 127 Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol 2007; 99: 6B-14B
• 128 Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81
• 129 Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 2005; 54: 1-7
• 130 Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007; 55: 498-510
• 131 Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15: 44-54
• 132 Ceriello A, Giacomello R, Stel G. , et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995; 44: 924-8
• 133 Stone KE, Chiquette E, Chilton RJ. Diabetic endovascular disease: role of coronary artery revascularization. Am J Cardiol 2007; 99: 105B-12B
• 134 Undas A, Wiek I, Stepien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diab Care 2008; 31: 1590-5
• 135 Vaidyula VR, Rao AK, Mozzoli M. , et al. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006; 55: 202-8
• 136 Blaas I, Heinz K, Wurtinger P. , et al. Vein graft thrombi, a niche for smooth muscle cell colonization - a hypothesis to explain the asymmetry of intimal hyperplasia. J Thromb Haemost 2016; 14: 1095-104
• 137 Stolla MC, Li D, Lu L, Woulfe DS. Enhanced platelet activity and thrombosis in a murine model of type I diabetes are partially insulin-like growth factor 1-dependent and phosphoinositide 3-kinase-dependent. J Thromb Haemostasis 2013; 11: 919-29
• 138 Rohatgi T, Henrich-Noack P, Sedehizade F. , et al. Transient focal ischemia in rat brain differentially regulates mRNA expression of protease-activated receptors 1 to 4. J Neurosci Res 2004; 75: 273-9
• 139 Muehlschlegel JD, Perry TE, Liu KY. , et al. Polymorphism in the protease-activated receptor-4 gene region associates with platelet activation and perioperative myocardial injury. Am J Haematol 2012; 87: 161-6
• 140 Edelstein LC, Simon LM, Lindsay CR. , et al. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood 2014; 124: 3450-8
• 141 Hamilton JR, Cornelissen I, Coughlin SR. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemostasis 2004; 2: 1429-35
• 142 Sabri A, Muske G, Zhang H. , et al. Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res 2000; 86: 1054-61
• 143 Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64
• 144 French SL, Arthur JF, Lee H. , et al. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. J Thromb Haemost 2016; 14: 1642-54
• 145 Lindahl TL, Macwan AS, Ramstrom S. Protease-activated receptor 4 is more important than protease-activated receptor 1 for the thrombin-induced procoagulant effect on platelets. J Thromb Haemost 2016; 14: 1639-41
• 146 Chen HS, Kuo SC, Teng CM. , et al. Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives. Bioorg Med Chem 2008; 16: 1262-78
• 147 Young SE, Duvernay MT, Schulte ML, Lindsley CW, Hamm HE. Synthesis of indole derived protease-activated receptor 4 antagonists and characterization in human platelets. PloS One 2013; 8: e65528
• 148 Holinstat M, Bray PF. Protease receptor antagonism to target blood platelet therapies. Clin Pharm Ther 2016; 99: 72-81
• 149 Dugina TN, Kiseleva EV, Chistov IV, Umarova BA, Strukova SM. Receptors of the PAR family as a link between blood coagulation and inflammation. Biochem 2002; 67: 65-74
• 150 Ramachandran R. Developing PAR1 antagonists: minding the endothelial gap. Disc Med 2012; 13: 425-31
• 151 Weiler H, Ruf W. ACTIVATED PROTEIN C IN SEPSIS: THE PROMISE OF NON-ANTICOAGULANT ACTIVATED PROTEIN C. Curr Opin Hematol 2008; 15: 487-93
• 152 Kerschen EJ, Fernandez JA, Cooley BC. , et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C. J Exp Med 2007; 204: 2439-48
• 153 Ferkau A, Gillmann HJ, Mischke R. , et al. Infection-associated platelet dysfunction of canine platelets detected in a flow chamber model. BMC Vet Res 2013; 9: 112
• 154 Totani L, Dell'Elba G, Martelli N. , et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. Thromb Haemost 2012; 107: 1130-40
• 155 Camerer E, Cornelissen I, Kataoka H. , et al. Roles of protease-activated receptors in a mouse model of endotoxemia. Blood 2006; 107: 3912-21
• 156 Camerer E, Duong DN, Hamilton JR, Coughlin SR. Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency. Blood 2004; 103: 152-4
• 157 Morrow DA, Braunwald E, Bonaca MP. , et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-13
• 158 Tricoci P, Huang Z, Held C. , et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33
• 159 Wong PC, Seiffert D, Bird JE. , et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Science Transl Med 2017; 9: 371
• 160 Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 2008; 14: 429-40
• 161 Bunnett NW. Protease-activated receptors: how proteases signal to cells to cause inflammation and pain. Semin Thromb Hemost 2006; (32 Suppl 1): 39-48
• 162 Cirino G, Severino B. Thrombin receptors and their antagonists: an update on the patent literature. Exp Opin Ther Patents 2010; 20: 875-84
• 163 Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-14
• 164 Hamilton JR. Protease-activated receptors as targets for antiplatelet therapy. Blood Rev 2009; 23: 61-5
• 165 Hirano K, Kanaide H. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb 2003; 10: 211-25
• 166 Krupiczojc MA, Scotton CJ, Chambers RC. Coagulation signalling following tissue injury: focus on the role of factor Xa. Int J Biochem Cell Biol 2008; 40: 1228-37
• 167 Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev 2001; 53: 245-82
• 168 Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res 2001; 88: 987-97
• 169 Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003; 1: 1495-503
• 170 Saban R, D'Andrea MR, Andrade-Gordon P. , et al. Regulatory network of inflammation downstream of proteinase-activated receptors. BMC physiology 2007; 7: 3
• 171 Traynelis SF, Trejo J. Protease-activated receptor signaling: new roles and regulatory mechanisms. Curr Opin Hematol 2007; 14: 230-5
• 172 Trejo J. Protease-activated receptors: new concepts in regulation of G protein-coupled receptor signaling and trafficking. J Pharmacol Exp Ther 2003; 307: 437-42
• 173 Wang H, Ubl JJ, Reiser G. Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. Glia 2002; 37: 53-63